HIV Treatment Bulletin - Vol. 7, No. 7/8, July/August 2006

Introduction

The annual resistance meeting is a closed workshop for around 200 delegates, nearly all of whom are presenting authors for research papers that are discussed at the meeting.

Although much of the meeting is focused on basic science, there are always studies with important implications for current clinical practice.

The following reports are included in this years review of the meeting.

• Resistance implications of monotherapy with lopinavir/r (Kaletra)
• Ritonavir reduces virological failure and resistance in treatment naïve patients treated with atazanavir
• Resistance to darunavir (TMC-114): predicting responses for treatment experienced patients
• Epidemiological studies and transmission of resistance: evidence for optimism – or issues with interpretation?
• • Overview of epidemology studies
  • Methamphetamine use linked to transmission of drug resistance
  • Transmission of resistance to T-20
• K103N containing variants persist longer in women with subtype D and with higher viral loads
• No subtype-based differences in baseline levels of K103N-containing variants in women receiving single dose nevirapine
• Phenotypic NNRTI resistance and genetic diversity in antiretroviral naïve women
• High prevalence of the K65R mutation in Botswana patients treated with ddI/d4T-based regimens
• Potential for easier selection of K65R mutation with tenofovir pressure in subtype C HIV-1 isolates
• Limitations in online tools to identify HIV-1 subtypes
• Categorisation of transmitted HIV drug resistance using the WHO/CDC HIV drug resistance threshold survey method may be useful in resource limited settings
• Resistance implications from PrEP and microbicide studies in macaques
• Low-level resistance linked to treatment failure: a role for more sensitive testing for naïve patients
• Testing for resistance after starting treatment

Abstracts from the workshop are published as a supplement to Antiviral Therapy (2006). Pdf files for abstracts from each section of the conference are available free online (click link to Antiviral Therapy, and scroll down to the bottom of the page):

Abstracts from the workshop

Abstracts are also published online at the excellent conference database published by aegis.org where individual abstract pdf files can also be downloaded.

excellent conference database published by aegis.org

2006-07-10
IB060707-03

©2006. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.